Lung Cancer Symposium – Early Diagnosis & Screening, Benchmarking the Nordics
You are invited to join the second Nordic Lung Cancer Symposium.
Join this symposium and take part in discussions with experts as they frame the challenges of lung cancer and address clinical models for risk prediction, early diagnosis and screening plans in the Nordics. International experts from the UK and USA will share up-to-date experiences from their respective countries. A panel discussion will include implementation models for selection and CT screening.
Tentative Program
| 10:00–10:10 | Welcome / Introductions Charlotte Homme, Head of Membership & Events, Oslo Cancer Cluster (confirmed) Ingrid Stenstadvoll Ross, CEO, Norwegian Cancer Society (Invited) Ole Alexander Oppdahlshei (Invited) |
| 10:10–10:30 | The challenges and benefits of lung cancer screening Oluf Dimitri Røe, MD, PhD, Professor, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU/Norwegian University of Science and Technology, Department of Oncology, Levanger Hospital, Norway. Lung Symposium, Chair, moderator. (Confirmed) |
| 10:30–11:00 | Lung Cancer Screening: Lessons from the United Kingdom David Baldwin, MD, PhD, Professor, Nottingham University Hospital. Nottingham, UK (Confirmed) |
| 11:30–11:50 | Finland – Efforts and progress in lung cancer screening Aija Knuuttila, MD, PhD, Associate Professor, Department of Medicine, HUS Comprehensive Cancer Center, Helsinki, Finland (Invited) |
| 11:50–12:10 | Iceland – Efforts and progress in lung cancer screening Hronn Haroardottir, Pulmonologist, Landspitali University Hospital (Confirmed) |
| 12:10-12:40 | Lunch & Networking Session |
| 12:00 – 13:00 | Sweden – Efforts and progress in lunch cancer screening Bengt Bergman, MD, PhD, Professor, Gothenburg University, National Working Group for Lung Cancer Care, Sweden (Invited) |
| 13:00 – 13:30 | Denmark – Efforts and progress in lunch cancer screening, and the PLUS Project Michael Stenger, MD, PhD, Associate Professor, PLUS Project Director, Svendborg Hospital, Odense, Denmark (Confirmed) |
| 13:30 – 14:15 | Norway – E-Lung Study, Innovative Models for Screening Selection and Smoking Cessation Progress Report and The TIDL Study. Oluf Dimitri Røe, MD, PhD, Professor, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU/Norwegian University of Science and Technology, Department of Oncology, Levanger Hospital, Norway (Confirmed) Toai Duc Nguyen, MD, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU/Norwegian University of Science and Technology, Department of Oncology, Levanger Hospital, Norway (Confirmed) Haseen Ashraf, Associate Professor, University of Oslo, Oslo, Department of Imaging, Akershus University Hospital, Oslo, Norway (Invited) |
| 14:15 – 14:30 | Coffee Break |
| 14:30 – 15:00 | Lung Cancer Screening in the United States: What Works, What Doesn’t Florian Fintelmann, MD, Associate Professor, Massachusetts General Hospital, Boston (Digital) |
| 15:00 – 16:00 | Panel Discussion and Conclusions: This is the right time to implement lung cancer screening in Norway Panelists, All speakers, plus stakeholders. |
The symposium is:
Organized by: Oslo Cancer Cluster & Levanger Hospital, Norwegian University of Science & Technology
Sponsored by: AstraZeneca & Daiichi Sankyo
Register to attend below
